Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Other financing activities: 2012-2023

Historic Other financing activities for Adma Biologics (ADMA) over the last 2 years, with Dec 2023 value amounting to $2.4 million.

  • Adma Biologics' Other financing activities rose 3265177.78% to $2.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was $5.1 million, marking a year-over-year increase of 365.31%. This contributed to the annual value of $2.4 million for FY2023, which is 15.52% down from last year.
  • Latest data reveals that Adma Biologics reported Other financing activities of $2.4 million as of Q4 2023, which was up 3,265,177.78% from $72 recorded in Q4 2022.
  • In the past 5 years, Adma Biologics' Other financing activities registered a high of $2.4 million during Q1 2022, and its lowest value of -$1.7 million during Q3 2020.
  • Its 2-year average for Other financing activities is $1.3 million, with a median of $1.4 million in 2022.
  • Data for Adma Biologics' Other financing activities shows a peak YoY skyrocketed of 3,265,177.78% (in 2023) over the last 5 years.
  • Adma Biologics' Other financing activities (Quarterly) stood at $123,899 in 2019, then reached -$1.7 million in 2020, then reached $72 in 2022, then spiked by 3,265,177.78% to $2.4 million in 2023.
  • Its Other financing activities stands at $2.4 million for Q4 2023, versus $72 for Q4 2022 and $404,562 for Q3 2022.